Caged Glutamate Compounds

Products
Literature
Cat. No. Product Name / Activity
6553 JF-NP-26
Caged Raseglurant (Cat. No. 4416)
5785 MDNI-caged-L-glutamate
Stable photoreleaser of L-glutamate
2225 MNI caged kainic acid
Caged kainic acid
2224 MNI-caged-NMDA
Caged NMDA
1490 MNI-caged-L-glutamate
Stable photoreleaser of L-glutamate
2277 MNI-caged-D-aspartate
Caged D-aspartate; ; NMDA agonist
3331 NPEC-caged-(1S,3R)-ACPD
Caged (1S,3R)-ACPD
3330 NPEC-caged-(S)-3,4-DCPG
Caged (S)-3,4-DCPG
3840 NPEC-caged-(S)-AMPA
Caged (S)-AMPA
4230 NPEC-caged-D-AP5
Caged D-AP5 (Cat.No. 0106)
3332 NPEC-caged-LY 379268
Caged group II mGlu receptor agonist
3574 RuBi-Glutamate
Caged glutamate; excited by visible wavelengths

Literature for Caged Glutamate Compounds

Tocris offers the following scientific literature for Caged Glutamate Compounds to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.